TriangleHEALTH PROFESSIONAL · SOURCE READING
Temsirolimus
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Temsirolimus is an intravenously administered mTOR inhibitor.
Evidence (temsirolimus):
A phase III randomized controlled trial enrolled intermediate- and poor-risk patients with a variety of subtypes of renal cell carcinoma. The trial was not restricted to clear cell kidney cancer.
A phase III randomized controlled trial enrolled intermediate- and poor-risk patients with a variety of subtypes of renal cell carcinoma. The trial was not restricted to clear cell kidney cancer.
Temsirolimus was shown to result in prolonged OS compared with interferon alfa.
A phase III randomized controlled trial enrolled intermediate- and poor-risk patients with a variety of subtypes of renal cell carcinoma. The trial was not restricted to clear cell kidney cancer.
The HRdeath was 0.73 (95% CI, 0.58–0.92; P = .008), making temsirolimus the only therapy for renal cell carcinoma to clearly show results in longer OS than did interferon alfa using conventional statistical analysis.[31]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice